Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities
Net (loss)/income	$ (42,603)	$ (22,548)	$ 6,094
Adjustments to reconcile net loss to net cash and cash equivalents provided by operating activities:
Stock-based compensation	10,489	12,936	9,217
Deferred taxes	(16,754)	(13,205)	(9,134)
Depreciation and amortization	47,252	44,638	44,612
Acquired in-process research and development ("IPR&D")	0	3,753	2,324
Non-cash interest	2,512	1,876	7,024
Contingent consideration fair value adjustment	500	0	0
Loss on extinguishment of debt	1,458	0	0
Asset impairment charge	2,374	445	75
Gain on sale of ANDAs	(1,822)	0	0
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	(5,548)	(23,664)	(7,287)
Inventories, net	3,224	(2,759)	(7,660)
Prepaid expenses and other current assets	127	(1,866)	403
Accounts payable	10,166	(2,294)	5,039
Accrued royalties	(267)	1,323	(3,372)
Current income taxes payable, net	(7,573)	4,982	(6,098)
Accrued government rebates	(3,078)	(1,075)	(73)
Returned goods reserve	6,503	10,369	4,043
Accrued expenses, accrued compensation, and other	(3,638)	2,356	424
Net Cash and Cash Equivalents Provided by Operating Activities	3,322	15,267	45,631
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	(84,494)	0	0
Acquisition of product rights, IPR&D, and other related assets	(21,081)	(62,187)	(20,914)
Acquisition of property and equipment, net	(2,557)	(6,135)	(6,635)
Proceeds from the sale of long-lived assets	2,649	0	0
Net Cash and Cash Equivalents Used in Investing Activities	(105,483)	(68,322)	(27,549)
Cash Flows From Financing Activities
Payments on Term Loan and Delayed Draw Term Loan agreements	(10,862)	(8,034)	(2,707)
Borrowings under Delayed Draw Term Loan agreement	0	0	118,000
Payments on Revolver agreement	0	(7,500)	0
Borrowings under Revolver agreement	24,000	15,000	0
Repayments of Credit Facility	(200,148)	0	0
Borrowings under the Credit Facility	300,000	0	0
Proceeds from issuance of convertible preferred stock	25,000	0	0
Convertible preferred stock dividends paid	(190)	0	0
Proceeds from issuance of common stock in public offering	75,000	0	0
Cash paid for costs of share issuances	(5,416)	0	0
Proceeds from stock option exercises and ESPP purchases	2,069	618	5,738
Repayment of Convertible Notes	0	0	(118,750)
Payments of debt issuance costs	(13,968)	0	0
Treasury stock purchases for restricted stock vests	(890)	(1,523)	(1,031)
Net Cash and Cash Equivalents Provided by/(Used in) by Financing Activities	194,595	(1,439)	1,250
Net Change in Cash and Cash Equivalents	92,434	(54,494)	19,332
Cash and cash equivalents, beginning of period	12,867	67,361	48,029
Cash and cash equivalents, end of period	105,301	12,867	67,361
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents	7,864	62,332	43,008
Restricted cash	5,003	5,029	5,021
Cash and cash equivalents, beginning of period	12,867	67,361	48,029
Reconciliation of cash, cash equivalents, and restricted cash, end of period
Cash and cash equivalents	100,300	7,864	62,332
Restricted cash	5,001	5,003	5,029
Cash and cash equivalents, end of period	105,301	12,867	67,361
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	9,705	6,931	6,092
Cash paid for income taxes	10,371	4,984	10,033
Supplemental non-cash investing and financing activities:
Fair value of contingent consideration in a business combination	30,500	0	0
Fair value of equity issued as consideration in a business combination	91,199	0	0
Acquisition of product rights, IPR&D, and other related assets included in returned goods reserve and derivatives and other non-current liabilities	0	391	500
Property and equipment purchased and included in accounts payable	$ 152	$ 172	$ 723